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In this study we provide evidence for the involvement of protein kinase C (PKC) in phorbol diester-induced phosphatidyl- 
choline (PC) hydrolysis by the phospholipase D pathway. Rat embryo fibroblasts (REF52) were prelabeled with either 
tritiated choline or my&tic acid; these compounds are preferentially incorporated into cellular PC. Phorbol diester-in- 
duced PC degradation was determined by measuring the release of PHIcholine, and the formation of PHlmyristoyl-con- 
taining phosphatidate (PA), diacylglycerol (DG), and phosphatidylethanol (PE). Staurosporine, aPKC inhibitor, blocked 
from 73 to 90% of the phorbol diester-induced PC hyrolysis. The inhibition of phorbol diester-induced choline release 
by staurosporine was dose dependent with an approximate ED,, of 150 nM. Pretreatment of cells with phorbol diester 
inhibited subsequent phorbol diester-induced PC degradation by 78-92s. A close correlation between the EDs0 for 
phorbol diester-stimulated choline release and the & for phorbol diester binding was demonstrated. Neither forskolin 
nor dibutyryl CAMP elicited cellular PC degradation. In vitro experiments using phospholipase D from Streptomyces 
chromofuscus showed that staurosporine did not inhibit and TPA did not stimulate nzyme activity. 
Protein kinase C; Phospholipase D; Phorbol diester; Phosphatidylcholine; Diacylglycerol 
1. INTRODUCTION 
The classical pathway for agonist-induced 
generation of cellular DG is via the hydrolysis of 
polyphosphoinositides by phospholipase C [ 11. 
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Abbreviations: DG, diacylglycerol; PKC Ca’+-activated, 
phospholipid-dependent protein kinase &; TPA, 12-0- 
tetradecanoyl phorbol-13-acetate; PC, phosphatidylcholine; 
PDBu, phorbol dibutyrate; BuzcAMP, 2’-O-dibutyryl- 
adenosine 3 ’ ,5 ‘-cyclic monophosphate; BSA, bovine serum 
albumin; MezSO, dimethyl sulfoxide; DiC8, dioctanoyl 
glycerol; PBS, phosphate-buffered saline; TLC, thin-layer 
chromatography; IP3, myo-inositol 1,4,5_trisphosphate; PE, 
phosphatidylethanol. In the naming of PC, PA, DG and PE, 
we do not distinguish between the type of aliphatic linkage to 
glycerol (ester, ether) 
This early hormone- and growth factor-elicited 
event results in the liberation of DG second 
messengers that stimulate PKC [2]. Use of the 
tumor promoter, TPA, has facilitated the study of 
biological events downstream from hormone and 
growth factor receptor-mediated events. This is 
because TPA interacts directly with PKC [3,4] and 
thereby circumvents the initial lipid metabolic 
steps that are a characteristic of cellular responses 
to a variety of natural agonists. Several 
laboratories have reported on a PC pathway of DG 
production in cultured cells [5- 111. The discovery 
of this pathway is of interest because it provides an 
additional source of lipid mediators from non- 
phosphoinositide stores. 
It is often assumed that TPA provokes changes 
in lipid metabolism through a PKC-related 
mechanism. Using PKC inhibitors, Parker et al. 
[12] have shown that PKC is involved in phorbol 
ester-stimulated arachidonic acid release. In an ef- 
fort to elucidate the mechanisms and biological 
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significance of the PC degradation pathway, we 
have been investigating this response in a cultured 
rat embryo-derived cell line, REF52. Our previous 
findings demonstrate that DG generated during 
TPA treatment originates from cellular PC [lo] by 
a pathway involving activation of phospholipase D 
[13]. We have, in this study, investigated the par- 
ticipation of PKC in phorbol diester-induced 
hydrolysis of cellular PC by the phospholipase D 
pathway. The data demonstrate that stauro- 
sporine, a PKC inhibitor [14], and down- 
regulation of PKC were dually effective in sup- 
pressing TPA-induced PC degradation. These 
results provide evidence that PKC mediates phor- 
bol diester induction of PC hydrolysis by phos- 
pholipase D. 
2. MATERIALS AND METHODS 
2.1. Materials 
[9,10(N)-‘HJMyristic acid (20-40 Ci/mmol) was purchased 
from New England Nuclear and Amersham. 
[methyl-‘HICholine chloride (80 Ci/mmol), L-myo- 
[ 1,2-‘H(N)]inositol (60 Ci/mmol) and [20-‘H(N)]PDBu 
(lo-20 Ci/mmol) were purchased from New England Nuclear. 
TPA and PDBu were supplied by Chemicals for Cancer 
Research (Eden Prairie, MN). Phospholipase C (B. cereus), 
phospholipase D (S. chromofwcus) and Bu2cAMP were from 
Sigma. Neutral lipids and phospholipids were purchased from 
Nu Chek Prep (Elysian, MN) and Avanti Polar Lipids (Bir- 
mingham, AL), respectively. Silica gel G TLC plates were from 
Analtech (Newark, DE) and FBS was purchased from Hy- 
Clone (Logan, UT). Forskolin was purchased from 
Calbiochem. Staurosporine was kindly provided by Dr Hiroshi 
Kase (Kyowa Hakko Kogyo Co., Ltd, Tokyo Research 
Laboratories, Tokyo). 
2.2. Ceil radiolabeling, treatment, and enzyme assay 
REF52 cells were cultured and prelabeled with [3H]myristic 
acid (1 or 24 h) or [‘HIcholine (24 or 48 h) as described in 
[10,11,13]. When cells were prelabeled for 24 h with 
[3H]myristic acid, medium containing 5% FBS was used. TPA 
(8 x 10e8 M) was added as detailed [lo]. Staurosporine 
(2.0 mM solution, MezSO) was diluted with medium to achieve 
the concentrations desired; MezSO was present in control 
cultures. Experiments were carried out in serum-free medium 
containing BSA [13]. For pre-exposure to phorbol diesters, cells 
were cultured in 5% FBS medium f PDBu (1 x 10e6 M) and 
[‘HIcholine for 24 h. After removal of isotope, cultures were 
equilibrated as in [13] before initiating experiments. DiC8 was 
prepared by phospholipase C (I?. cereus) digestion [lo] of dioc- 
tanoylphosphatidylcholine. PE formation was assessed using 
cells prelabeled with [3H]myristic acid (24 h) and medium con- 
taining 0.7% ethanol during the treatment period. The in- 
fluence of TPA and staurosporine on in vitro phospholipase D 
(S. chromofuscus) activity was also evaluated; the assays [15] 
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employed phosphatidyl[‘4C]choline (2.0 mM), synthesized as 
detailed [lo] and diluted with egg PC (spec. act. 
470 dpm/nmol). The incubations (10-15 min, 5-20 U en- 
zyme/ml) were terminated by addition of solvents [16], and 
[“‘C]choline was quantitated as described [lo]. 
BuzcAMP (1 .O mM) was tested alone or in combination with 
TPA (30 min at 37’C) using cells prelabeled with [‘HIcholine. 
The influence of forskolin (Me#O vehicle) on PC degradation 
was examined in cells prelabeled with [‘HIcholine and 
[‘Hlmyristic acid (separate experiments). Cultures were in- 
cubated for 15 min at 37°C (+ forskolin) and PC metabolism 
was analyzed as detailed above. PDBu specific binding was 
determined as described [17]. Phosphoinositide degradation 
was measured 1181 after cells had been labeled for 48 h with 
[‘Hlinositol (10 &i/ml 10% FBS medium). 
2.3. Lipid analysis 
Total cellular lipids were extracted [16] as previously detailed 
[lo]. Phosphatidate (dioleoyl) carrier (25 pg) was added to each 
extraction. Radiolabeled DC and phosphatidate were resolved 
from total lipids using the solvent systems described in [10,13]. 
PE was resolved from total cellular lipids by TLC in a solvent 
system containing chloroform/methanol/NH40H (65 : 30 : 3, 
v/v). Lipids were visualized using iodine [10,13], and radioac- 
tivity was determined by liquid scintillation spectrometry. 
[‘HICholine released into the culture medium was determined 
as in [13,19]. 
3. RESULTS 
TPA and DiC8, agents known to stimulate PKC 
[3,4,20], were employed in initial experiments to 
investigate the relationship between PKC activa- 
tion and PC hydrolysis by the phospholipase D 
pathway. In cells labeled with [3H]myristic acid, 
10 min treatment with TPA (8 x 10e8 M) or DiC8 
(7.5 x 10m5 M) elicited an approx. 5- and 7-fold in- 
crease over control in [3H]PA formation, respec- 
tively. This was accompanied by a 2-2.5fold 
increase in [3H]DG. Additional experiments 
revealed that radioactivity in PC was diminished 
by 18%, compared to control cultures (control, 
6598 cpm + 200; TPA, 5417 cpm f 183; P < 
O.OOOl), when cells were treated with TPA for 1 h. 
The dose-response relationship for phorbol 
diester-induced choline release and the binding of 
phorbol diesters to REF52 cells were also 
evaluated. The data in fig.1 show that increasing 
the concentration of PDBu causes an increase in 
the release of t3H]choline (ED50 - 28 nM). The & 
for PDBu binding to REF52 cells was -32 nM 
(personal communication, Dr Susan Jaken, W. 
Alton Jones Cell Science Center). 
Protocols commonly used to attenuate PKC ac- 
tivity were employed to examine further the 
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Fig. 1. Dose-response relationship for phorbol diester-induced 
PC hydrolysis by phospholipase D in REF52 cells. Cultures 
were labeled with [‘HIcholine (1 .O &i/ml medium) for 24 h, 
equilibrated as described in section 2, and exposed to increasing 
concentrations of PDBu for 60 min. All cultures contained 
MezSO (0.02%). [3H]Choline released to the medium was 
quantitated as described in the text. Results represent means f 
SD (n = 3 for each point); variances were C 10% of the mean. 
Repeated experiments gave similar results. 
association between PKC and phospholipase D. 
Fig.2 shows that staurosporine, a PKC inhibitor 
[ 141, blocked TPA-induced [‘HIcholine release in a 
dose-dependent fashion (ED50 - 150 nM). The ef- 
fect of staurosporine on TPA-induced PC 
hydrolysis was also measured by (in addition to 
choline release) the generation of two direct 
hydrophobic degradation products of phospho- 
lipase D, PA and PE, and formation of one in- 
direct product, DG. The data in table 1 show that 
staurosporine inhibited TPA-induced PC 
hydrolysis as measured by all four parameters. 
TPA caused a 2.1 -fold increase in choline release, 
whereas staurosporine decreased this to near con- 
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Fig.2. The inhibitory influence of staurosporine on phorbol 
diester-induced PC degradation by the phospholipase D 
pathway in REF52 cells. Cultures were prelabeled with 
[‘HIcholine, equilibrated, incubated in the absence or presence 
of staurosporine at the concentrations indicated, and exposed 
to TPA (20 min) as described in the text. Variances were < 5% 
of the mean; n = 3 for each point (+ SD). Total response in the 
absence of staurosporine is 100%. 
trol values (inhibition of -9OYo). Concomitant 
with this response, staurosporine inhibited TPA- 
induced PA formation by -76% and 
phospholipase D-catalyzed PE synthesis by -91%. 
The production of DG was likewise inhibited by 
staurosporine (90070). 
Experiments were conducted using down- 
regulation protocol, a valuable technique for 
assessing PKC-mediated cellular events. The data 
in table 2 show that pretreatment of cells with 
PDBu largely inhibited subsequent phorbol 
diester-induced choline, PA, and DG formation. 
In cultures preexposed to PDBu, phorbol diester- 
induced [3H]choline release was inhibited by 
-86%, and [3H]PA formation was reduced by 
-78%. The generation of [3H]DG was likewise in- 
hibited (-92%). 
The effects of staurosporine. and phorbol 
diesters were examined on several other enzymatic 
responses. Vasopressin, which induces PC 
hydrolysis in REF52 cells [ 10,l 1,131, also elicits 
polyphosphoinositide hydrolysis in this cell line. 
87 
Volume 245, number I,2 FEBS LETTERS March 1989 
Table 1 
The influence of the PKC inhibitor, staurosporine, on TPA-induced PC hydrolysis in 
REF52 cells: inhibited formation of hydrophilic and hydrophobic degradation 
products 
Cell treatment PC hydrolysis products (cpm metabolites/culture) 
Hydrophilic Hydrophobic 
[3H]Choline [‘HIPA [‘H]DG [3H]PE 
Control 2021 f 195 1890 f 120 3035 + 115 1200 f 140 
TPA 4212 f 136 6550 * 210 4910 f 275 3685 + 145 
Staurosporine 1859 * 172 1690 + 120 3260 f 115 1590 f 105 
Staurosporine + TPA 2057 + 183 2805 + 255 3480 + 145 1820 + 195 
Cells were prelabeled with either [‘HIcholine or [‘Hlmyristic acid as described in 
section 2, and then preincubated in control (0.25% MezSO) or staurosporine (5 x 
10m6 M) medium for 3 min at room temperature. TPA (8 x 10-a M) was added, and 
cells were further incubated at 37°C for 30 min ([‘HJcholine), 10 min ([‘Hlmyristoyl- 
PA; [‘Hlmyristoyl-DG) or 15 min ([3H]myristoyl-PE). PC hydrolysis products were 
determined as described in the text. All values shown are mens + SD (n = 3) for each 
experimental group. [‘HIPA and [3H]DG were analyzed from the same experiment; 
[‘HIcholine and [“HIPE data represent separate xperiments 
Vasopressin (100 ng/ml, 30 s) caused a 6.5fold in- 
crease in the amount of [3H]IP3 (not shown). 
Under identical conditions, staurosporine (5 PM) 
had no influence on vasopressin-induced [3H]IP3 
formation. Staurosporine (5 PM) did not modify 
the hydrolysis of phosphatidyl[i4C]choline when 
assayed in vitro using phospholipase D from S. 
chromofuscus. Lastly, to determine whether TPA 
interacted directly with phospholipase D, in vitro 
assays using enzyme from S. chromofuscus were 
conducted; over the concentration range tested 
(3 x lo-*-8 x lo-’ M), TPA had no influence on 
enzyme activity. 
The possible participation of an adenylate 
cyclase/cAMP mechanism in PC degradation was 
examined. In cells prelabeled with [3H]choline, 
Table 2 
Pretreatment of REF52 cells with PDBu inhibits phorbol diester-induced PC 
degradation by the phospholipase D pathway 
Agonist PDBu PC hydrolysis products 
pretreatment (cpm metabolites/culture) 
[‘HICholine [3H]PA [‘H]DG 
Control - 1368 + 115 4365 i 190 3655 + 135 
Phorbol diester _ 3996 + 105 12150 + 570 6440 f 495 
Control + 1531 * 79 4665 + 150 3645 + 35 
Phorbol diester + 1939 f 38 6675 + 210 3865 + 135 
Cells were prelabeled with either [‘HIcholine or [‘Hlmyristic acid, in the 
absence or presence of PDBu (1 x 10m6 M) for 24 h. [‘HICholine-labeled cells 
were challenged with PDBu (8 x IO-’ M) for 30 min, and cultures labeled with 
[3H]myristic acid were challenged with TPA (8 x lo-* M) for 10 min at 37°C. 
The presence of PDBu during the prelabeling period did not alter uptake or 
incorporation of isotopes (vs controls). PC hydrolysis products, [3H]choline, 
[3H]myristoyl-PA and [3H]myristoyl-DG, were determined as described in the 
text. All values are means f SD (n = 3) for each experimental group. [‘HIPA 
and [“H]DG were analyzed from the same experiment; similar results were 
obtained using PDBu as agonist 
88 
Volume 245, number 1,2 FEBS LETTERS March 1989 
BuzcAMP (1 .O mM, 30 min treatment) elicited on- 
ly a minor increase in the release of [3H]choline- 
containing compounds to the medium (21% above 
control). The influence of BuzcAMP, added 
together with TPA, did not increase or decrease 
cellular phospholipase D activity over that elicited 
by TPA alone. Exposure of cells to forskolin 
(5-25 pM, 15 min treatment) did not cause an in- 
crease in the release of [3H]choline metabolites 
over control levels, nor did forskolin elicit in- 
tracellular formation of [3H]PA or t3H]DG over 
control values (not shown). 
4. DISCUSSION 
Our results implicating PKC involvement in the 
phospholipase D pathway of PC degradation are 
based on: (i) elicitation of PC hydrolysis by PKC 
agonists; (ii) a close correlation between the EDso 
for choline release and the Kd for phorbol diester 
binding; (iii) impedance of phorbol diester-induced 
PC degradation by the PKC inhibitor, 
staurosporine; (iv) inhibition of phorbol diester- 
induced PC degradation by cellular pretreatment 
with phorbol diesters. Phospholipase D activity 
was also evaluated by the formation of in- 
tracellular PE; in the presence of ethanol the en- 
zyme catalyzes a transphosphatidylation reaction 
to produce PE [21,22]. By using several techniques 
to measure intracellular PC degradation, our 
results show that methods employed to block PKC 
action also elicit diminished phospholipase D ac- 
tivity. Staurosporine did not modify the action of 
phospholipase D (S. chromofuscus) when assayed 
in vitro. Furthermore, although we have no 
definitive data to dispel the notion that phorbol 
diesters stimulate intracellular phospholipase D 
directly, experiments employing phospholipase D 
from S. chromofuscus showed that TPA did not 
modify enzyme activity. 
Hormone-induced accumulation of PA by a 
phospholipase D mechanism has been 
demonstrated in hepatocytes [22]; the response 
could be activated, in vitro, by the addition of 
guanine nucleotides. As phorbol diesters circum- 
vent cellular transducing elements, our data would 
indicate that TPA, via interaction with PKC, 
stimulates phospholipase D activity by a 
mechanism that does not require an initial G- 
protein-coupled reaction. Similar conclusions were 
made for agonist-induced PE synthesis in HL-60 
cell lysates [23]. We have also shown that the PKC 
inhibitor, staurosporine, does not modify the G- 
protein-requiring pathway of vasopressin-induced 
PIP2 degradation in REF52 cells. 
Our data exemplify the diversity of biochemical 
responses elicited by the PKC family of isozymes 
[24,25]. A role for phospholipase D in agonist- 
induced cellular events was suggested, early on, in 
the work of Hokin-Neaverson and co-workers 
[26]. In the light of recent research, we postulate 
that the action of phospholipase D constitutes a 
key element in PA- and DG-governed cellular 
responses, and as such, phospholipase D could 
play an important role in the physiological regula- 
tion of agonist-induced events. 
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